Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT06339658
Recruiting Observational

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

NCT06339658 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitari de Bellvitge
Phase
Observational
Started
2021-01-01
Last updated
2026-09-17

Condition(s) studied

Breast CancerAxillary Metastases

Investigational drug(s) / intervention(s)

Targeted axillary dissection (TAD) by ICGTargeted axillary dissection (TAD) by Blue patent

Targeted axillary dissection (TAD) by ICG: Use of ICG during the targeted axillary dissection (TAD)

Targeted axillary dissection (TAD) by Blue patent: Use of Blue patent during the targeted axillary dissection (TAD)

Study summary

To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Breast cancer cN+ patients who undergo neadjuvant treatment. Exclusion Criteria: * Patients in whom there is a contraindication for the use of ICG. * Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.

Primary outcome measure(s)

  • Detection rate of sentinel lymph node between tracers — 2 years
    Compare the detection rate of sentinel lymph node between ICG and blue patent in cN+ patients after neoadjuvant treatment

Trial sites (1)

FacilityCityRegionStatus
Hospital de Bellvitge L'Hospitalet de Llobregat Barcelona Recruiting

More Hospital Universitari de Bellvitge trials in Spain

Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (SLIDY) Recruiting
Sarcopenia in Colorectal Cancer Patients, Intervention Study Recruiting
Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid Function Recruiting
Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry. Recruiting
Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy . Recruiting

Other trials for the same condition

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Recruiting
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Active, not recruiting
Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer Recruiting
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions Recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06339658 on ClinicalTrials.gov ↗ ← All trials in Spain